Cubist Pharmaceuticals (CBST) – Research Analysts’ Recent Ratings Updates

Cubist Pharmaceuticals (NASDAQ: CBST) received a number of ratings updates from brokerages and research firms in the last week:Cubist Pharmaceuticals had its “buy” rating re-affirmed by analysts at Bank of America.Cubist Pharmaceuticals had its “buy” rating re-affirmed by analysts at Jefferies Group. They now have a $50.00 price target on the stock.Cubist Pharmaceuticals had its “hold” rating re-affirmed by analysts at Needham & Company.Cubist Pharmaceuticals had its price target raised by analysts at RBC Capital from $46.00 to $49.00. They now have an “outperform” rating on the stock.Cubist Pharmaceuticals had its price target raised by analysts at Wedbush to $55.00.Cubist Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “neutral” rating to an “underperform” rating.